{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:31:05Z","timestamp":1792992665457,"version":"4.5.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Thiazide diuretics are a cornerstone for the treatment of hypertension, but their use is associated with development of hyponatremia. Women and older adults are particularly vulnerable, but population-based estimates of absolute risk are largely absent. Such data are a prerequisite for a robust risk-benefit assessment in the clinical setting.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare new use of thiazide diuretics with calcium channel blockers (CCBs) and subsequent risk of hyponatremia among different age groups and between the sexes.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This propensity score\u2013matched cohort study included 159\u202f080 individuals 18 years or older in the Stockholm Sodium Cohort, a research database established to investigate the association between thiazide and hyponatremia among individuals in Stockholm, Sweden, between July 1, 2006, and December 31, 2018. Statistical analysis was performed between January 2025 and January 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Newly initiated treatment with thiazide diuretics and CCBs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was profound hyponatremia (ie, a sodium concentration &amp;lt;125 mEq\/L). Secondary outcomes were sodium concentrations less than 130 mEq\/L and less than 135 mEq\/L.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 79\u202f540 individuals (median age, 63 years [IQR, 54-72 years]; 41\u202f275 women [51.9%]) initiating thiazide treatment were propensity score matched with 79\u202f540 individuals (median age, 63 years [IQR, 54-72 years]; 41\u202f168 women [51.8%]) receiving CCBs. The cumulative incidence of profound hyponatremia was 0.80% (95% CI, 0.74%-0.87%) for thiazide users and 0.46% (95% CI, 0.41%-0.51%) for CCB users during the first 2 years of treatment. The occurrence of profound hyponatremia with thiazide treatment was higher among women (cumulative incidence, 1.04% [95% CI, 0.94%-1.15%) and individuals 80 years or older (cumulative incidence, 2.40% [95% CI, 2.07%-2.73%]). Thus, among women 80 years or older, the number needed to harm (NNH) was 53 (95% CI, 41-73) for developing sodium concentrations less than 125 mEq\/L, 28 (95% CI, 22-38) for concentrations less than 130 mEq\/L, and 16 (95% CI, 13-20) for concentrations less than 135 mEq\/L. This was in marked contrast with women younger than 65 years, for whom the corresponding NNH was 790 (95% CI, 408-11\u202f966) for developing sodium concentrations less than 125 mEq\/L, 818 (95% CI, 303-\u221e) for concentrations less than 130 mEq\/L, and 120 (95% CI, 78-261) for concentrations less than 135 mEq\/L.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study comprising 159\u202f080 individuals, the association between newly initiated thiazide diuretics and hyponatremia was negligible among individuals younger than 65 years of age. In contrast, among older adults, especially among women, the association was substantial. The results may incentivize the prescriber toward choosing an alternative antihypertensive treatment. If thiazides are initiated, subsequent monitoring of serum sodium concentrations should be considered.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.4642","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:30:34Z","timestamp":1775143834000},"page":"e264642","source":"Crossref","is-referenced-by-count":5,"title":["Thiazides and Risk of Hyponatremia by Age and Sex"],"prefix":"10.1001","volume":"9","author":[{"given":"Cecilia","family":"Bergh Fahl\u00e9n","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Education at S\u00f6dersjukhuset, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Internal Medicine, Section of Diabetes and Endocrinology, S\u00f6dersjukhuset, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Falhammar","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatan D.","family":"Lindh","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buster","family":"Mannheimer","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education at S\u00f6dersjukhuset, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Internal Medicine, Section of Diabetes and Endocrinology, S\u00f6dersjukhuset, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"33","key":"zoi260169r1","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension.","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"zoi260169r2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"zoi260169r3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/bcp.12499","article-title":"A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?","volume":"79","author":"Barber","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"zoi260169r4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1053\/j.ajkd.2019.07.011","article-title":"Thiazide-associated hyponatremia: clinical manifestations and pathophysiology.","volume":"75","author":"Filippone","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"zoi260169r5","first-page":"175","article-title":"Thiazide-associated hyponatremia in the elderly: what the clinician needs to know.","volume":"13","author":"Liamis","year":"2016","journal-title":"J Geriatr Cardiol"},{"key":"zoi260169r6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejim.2025.04.034","article-title":"Drug-induced hyponatremia in clinical care.","volume":"137","author":"Mannheimer","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"10","key":"zoi260169r7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.","volume":"126","author":"Verbalis","year":"2013","journal-title":"Am J Med"},{"issue":"11","key":"zoi260169r8","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.amjmed.2011.06.031","article-title":"Risk of thiazide-induced hyponatremia in patients with hypertension.","volume":"124","author":"Leung","year":"2011","journal-title":"Am J Med"},{"issue":"3","key":"zoi260169r9","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afad026","article-title":"The differential risk of severe hyponatraemia based on the use patterns of hyponatraemia-inducing medications in older adults.","volume":"52","author":"Jun","year":"2023","journal-title":"Age Ageing"},{"issue":"1","key":"zoi260169r10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M23-1989","article-title":"Cumulative incidence of thiazide-induced hyponatremia: a population-based cohort study.","volume":"177","author":"Andersson","year":"2024","journal-title":"Ann Intern Med"},{"key":"zoi260169r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.annepidem.2024.01.005","article-title":"Establishment and representativeness of the Stockholm Sodium Cohort: a laboratorial and pharmacoepidemiologic database covering 1.6 million individuals in the Stockholm County.","volume":"91","author":"Issa","year":"2024","journal-title":"Ann Epidemiol"},{"issue":"4","key":"zoi260169r12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0002-9343(99)00055-8","article-title":"Hyponatremia: evaluating the correction factor for hyperglycemia.","volume":"106","author":"Hillier","year":"1999","journal-title":"Am J Med"},{"issue":"7","key":"zoi260169r15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00228-020-03086-6","article-title":"Association between newly initiated thiazide diuretics and hospitalization due to hyponatremia.","volume":"77","author":"Mannheimer","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"zoi260169r16","doi-asserted-by":"publisher","first-page":"e3696","DOI":"10.1210\/clinem\/dgaa194","article-title":"Associations between antihypertensive medications and severe hyponatremia: a Swedish population-based case-control study.","volume":"105","author":"Falhammar","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"zoi260169r17","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"zoi260169r13","unstructured":"The National Patient Register. The National Board of Health and Welfare. Accessed August 1, 2024. https:\/\/www.socialstyrelsen.se\/en\/"},{"key":"zoi260169r14","unstructured":"The longitudinal integrated database for health insurance and labour market studies (LISA). Statistics Sweden. Accessed February 19, 2026. https:\/\/www.scb.se\/vara-tjanster\/bestall-data-och-statistik\/register\/lisa\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847235\/bergh_fahln_2026_oi_260169_1782840813.0405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:16:45Z","timestamp":1782847005000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.4642","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}